The "omics" revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. New biomarkers are discovered each day and this rapid development promises excellent growth potential for the biomarker analysis market. However, due to various challenges faced in biomarker validation and assay development, there is a huge lag between the time that a biomarker is discovered in the laboratory and the time it is actually commercialized.
In an upcoming Analyst Briefing, Frost & Sullivan will therefore focus on the potential of the European Biomarker Analysis Market. The briefing will be held on Tuesday, 24th November 2009, at 3 p.m. GMT. Highlights of the briefing include an analysis of current trends, challenges, drivers and restraints, significant market developments, a survey of market opportunities and what lies ahead in this vibrant field.
"All stakeholders in the biomarker industry need to come together to circumvent the bottlenecks in this field," says Frost & Sullivan Senior Research Analyst Rasika Ramachandran. "Although the task of bringing together the entire industry for this cause is a formidable one, it seems to be the only solution to the challenge of making biomarker testing reach every drug discovery lab. The long term benefits of such an undertaking should aid in justifying the efforts that are involved in making it happen."
The discussion on the European Biomarker Analysis market will be beneficial to biomarker companies, pharmaceutical manufacturers, biotechnology companies, drug discovery firms and contract research organizations.
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation